GLP-1s

Extracted Attributes

• Category

  Class of Medications

• Therapeutic Class

  Glucagon-like peptide-1 receptor agonists (GLP-1RAs), Incretin mimetics

• Common Side Effects

  Nausea, Vomiting, Diarrhea, Abdominal pain, Constipation

• Mechanism of Action

  Mimics the natural GLP-1 hormone by activating GLP-1 receptors, enhancing insulin secretion, inhibiting glucagon release, delaying gastric emptying, and reducing food intake.

• Primary Medical Uses

  Type 2 diabetes, Long-term weight management, Anti-obesity medication, Metabolic-associated steatohepatitis

• Administration Routes

  Subcutaneous injection, Oral

• US Prescriptions (2023)

  Over 25 million

• US Prescription Ranking (2023)

  19th most commonly prescribed medication

Timeline

• Semaglutide, a prominent GLP-1, was approved for medical use in the US. (Source: Wikipedia)

  2017-01-01

• Semaglutide was the nineteenth most commonly prescribed medication in the United States, with more than 25 million prescriptions. (Source: Wikipedia)

  2023-01-01

Semaglutide

Semaglutide is an anti-diabetic medication used for the treatment of type 2 diabetes and an anti-obesity medication used for long-term weight management. It is a peptide similar to the hormone glucagon-like peptide-1 (GLP-1), modified with a side chain. It can be administered by subcutaneous injection or taken orally. It is sold by Novo Nordisk under the brand names Ozempic and Rybelsus for diabetes, and under the brand name Wegovy for weight management, weight loss, and the treatment of metabolic-associated steatohepatitis (nonalcoholic steatohepatitis). Semaglutide is a glucagon-like peptide-1 receptor agonist. The most common side effects include nausea, vomiting, diarrhea, abdominal pain, and constipation. It was approved for medical use in the US in 2017. In 2023, it was the nineteenth most commonly prescribed medication in the United States, with more than 25 million prescriptions.

Web Search Results

• GLP-1 receptor agonist

  Wikipedia The Free Encyclopedia ## Contents # GLP-1 receptor agonist Glucagon-like peptide-1 (GLP-1) receptor agonists, also known as GLP-1 analogs, GLP-1RAs, or incretin mimetics, are a class of anorectic drugs that reduce blood sugar and energy intake by activating the GLP-1 receptor. They mimic the actions of the endogenous incretin hormone GLP-1, which is released by the gut after eating. [...] GLP-1 agonists were initially developed for type 2 diabetes. The 2022 American Diabetes Association (ADA) standards of medical care in diabetes include GLP-1 agonists or SGLT2 inhibitors as a first-line pharmacological therapy for type 2 diabetes in patients who have or are at high risk for atherosclerotic cardiovascular disease or heart failure. They are also a first-line treatment for people with both type 2 diabetes and kidney disease. Both types of medication can be combined with metformin. [...] GLP-1 agonists were initially developed for type 2 diabetes. The 2022 American Diabetes Association standards of medical care recommend GLP-1 agonists as a first-line therapy for type 2 diabetes, specifically in patients with atherosclerotic cardiovascular disease or obesity. The drugs were also noted to reduce food intake and body weight significantly, and some have been approved to treat obesity in the absence of diabetes. They are also in development for other indications, such as

• Glucagon-like peptide-1 - Wikipedia

  Glucagon-like peptide-1 (GLP-1) is a 30- or 31-amino-acid-long peptide hormone deriving from tissue-specific posttranslational processing of the proglucagon peptide. It is produced and secreted by intestinal enteroendocrine L-cells and certain neurons within the nucleus of the solitary tract in the brainstem upon food consumption. The initial product GLP-1 (1–37) is susceptible to amidation and proteolytic cleavage, which gives rise to the two truncated and equipotent biologically active forms, [...] in the 2000s. [...] Alongside glucose-dependent insulinotropic peptide (GIP), GLP-1 is an incretin; thus, it has the ability to decrease blood sugar levels in a glucose-dependent manner by enhancing the secretion of insulin. Beside the insulinotropic effects, GLP-1 has been associated with numerous regulatory and protective effects. Unlike GIP, the action of GLP-1 is preserved in patients with type 2 diabetes. Glucagon-like peptide-1 receptor agonists gained approval as drugs to treat diabetes and obesity starting

• GLP-1 diabetes and weight-loss drug side effects - Harvard Health

  What are GLP-1 drugs and how do they work? ------------------------------------------ GLP-1 drugs, also called GLP-1 agonists, are shortened names for glucagon-like peptide-1 receptor agonists. GLP-1 receptor agonists mimic the GLP-1 hormone that is naturally released in the gastrointestinal tract in response to eating. [...] Ten GLP-1 drugs are FDA-approved to treat either type 2 diabetes or weight loss. Some GLP-1 agonists have the same generic name but are marketed under a different brand name and are approved for a different purpose, depending on the dose and how they are taken. [...] In people with type 2 diabetes, the body's cells are resistant to the effects of insulin, the body does not produce enough insulin, or both. GLP-1 agonists stimulate the pancreas to release insulin and suppress the release of another hormone called glucagon, both of which help control blood sugar levels in people with type 2 diabetes.

• GLP-1 Agonists

  GLP-1 agonists are most often injectable medications, meaning you inject a liquid medication with a needle and syringe. You give the shots in the fatty tissue just under your skin (subcutaneous injection). Areas of your body you can give the injections include your belly, outer thighs, upper buttocks and the backs of your arms. Other names for this medication class include: Glucagon-like peptide-1 agonists. GLP-1 receptor agonists. Incretin mimetics. GLP-1 analogs. [...] GLP-1 agonist medications work by mimicking this hormone. In medication terms, an agonist is a manufactured substance that attaches to a cell receptor and causes the same action as the naturally occurring substance. In other words, GLP-1 medications bind to GLP receptors to trigger the effects (or roles) of the GLP-1 hormone. The higher the dose of the GLP-1 agonist, the more extreme the effects.

• Glucagon-like peptide-1 receptor: mechanisms and advances in ...

  11, 178 (2020)."),48. 15, 740 (2022).") By emulating the biological activity of natural GLP-1, GLP-1RAs effectively fulfill the role of GLP-1, effectively lowering blood glucose levels without increasing the risk of hypoglycemia and demonstrating favorable safety profiles.49.") GLP-1RAs represent a pharmacotherapeutic category of injectable hypoglycemic agents that are sanctioned as adjunctive therapies to diet and exercise for the management of type 2 diabetes mellitus (T2DM) in adult patients [...] diabetes, cardiovascular disorders, and neurodegenerative diseases.5 12, 721135 (2021)."),6."),7.") GLP-1 is a peptide produced by the cleavage of proglucagon, mainly synthesized in the intestinal mucosal L-cells, pancreatic islet α-cells, and neurons in the nucleus of the solitary tract.3."),4.") GLP-1RAs mimic the action of endogenous GLP-1, activating GLP-1R, thereby enhancing insulin secretion, inhibiting glucagon release, delaying gastric emptying, and reducing food intake through central [...] GLP-1 is a peptide hormone generated through the enzymatic breakdown of proglucagon. It is synthesized in L-cells located in the intestinal mucosa, α-cells found in the pancreatic islet, and neurons residing in the nucleus of the solitary tract.29.") GLP-1, an endocrine hormone, is secreted by enteroendocrine L-cells located in the distal jejunum, ileum, and colon in response to nutrient ingestion and neuroendocrine stimulation. It originates from the preproglucagon precursor, which undergoes